Premium
Laminin receptor in lymph node negative breast carcinoma
Author(s) -
Nadji Mehrdad,
Nassiri Mehdi,
Fresno Manuel,
Terzian Edward,
Morales Azorides R.
Publication year - 1999
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19990115)85:2<432::aid-cncr22>3.0.co;2-j
Subject(s) - lymph node , medicine , breast carcinoma , pathology , immunohistochemistry , carcinoma , estrogen receptor , axillary lymph nodes , breast cancer , mammary gland , monoclonal antibody , antibody , cancer , immunology
BACKGROUND Expression of 67 kD laminin binding protein, 67LR, is reported to be associated with invasive and metastatic phenotypes in several types of human malignancies. In mammary carcinomas, however, the biologic role of 67LR has been less clear. The authors explored the potential biologic significance of expression of 67LR in 148 patients with axillary lymph node negative breast carcinoma. METHODS Formalin fixed, paraffin embedded histologic sections were immunohistochemically evaluated for 67LR using monoclonal antibody MLuC5. The staining results were correlated with morphologic data as well as with estrogen receptor content and p53 product accumulation. RESULTS There were statistically significant correlations between positivity for 67LR and lower histologic grade ( P = 0.003), lower nuclear grade ( P = 0.002), positivity for estrogen receptor ( P = 0.003), and lack of p53 abnormality ( P < 0.001). Expression of 67LR had no independent effect on the disease free or overall survival of lymph node negative patients with breast carcinoma. Nevertheless, in the subgroup of 67LR positive patients, positivity for estrogen receptor was associated with significantly longer overall survival ( P = 0.008). CONCLUSIONS The data from this study suggest that tissue expression of 67LR, as detected by antibody MLuC5, is associated with better differentiated, less aggressive forms of axillary lymph node negative breast carcinoma. Cancer 1999;85:432–6. © 1999 American Cancer Society.